As neoadjuvant therapy leads to tumor apoptosis and these macrophages have been shown to capture tumor-derived material, it could be hypothesized that the increase in CD169+ macrophages has a favorable role in response to neoadjuvant therapy. The gene discussed is SIGLEC1; the disease is neoplasm.